COMPUTATIONAL BIOLOGY
HelioSynth Bio: Programmable Enzyme Foundry Scaling to 9 Pharma Partnerships
APEX ENTRY CHECK
Led $4.5M Seed ($22M Post)
CURRENT MILESTONE
$490M Series B · 9 Pharma Deals
MANDATE TRACK
Institutional Seed Lead
01 // DAY-0 NON-CONSENSUS TECHNICAL INSIGHT
Pure in-silico AI bio startups stalled on wet-lab synthesis bottlenecks; HelioSynth coupled generative folding directly to a 10,000-variant/week microfluidic loop.
02 // POST-CHECK COMPUTE, LAB & TALENT EXECUTION
Spun IP cleanly out of ETH Zurich in 21 days, placed their VP of Bioprocess Engineering, and co-led their $38M Series A.
03 // COMMERCIAL TRAJECTORY & DISCLOSURE
Delivered catalytic enzymes with 40x higher thermal stability across 9 global pharmaceutical manufacturing agreements. Illustrative portfolio study; past results do not guarantee future performance.
01 // APEX VENTURES
DeepTech Seed & Series A
$420M Fund IV leading $1.5M–$12M checks in AI silicon, robotics, computational bio, and grid infrastructure.
02 // CAPITAL & PORTFOLIO
Mandate & Ledger
Clean 1x non-participating preferred governance plus $350K non-dilutive H100 compute access.
03 // PARTNERSHIP
Bench & Research
Every memo read directly by former-founder General Partners in San Francisco, New York, and Zurich.
04 // GOVERNANCE & DOCS
Disclosures & Manual
SEC/Advisers Act non-solicitation notices, founder confidentiality, and 12-station owner manual.
© 2026 APEX VENTURES MANAGEMENT LLC · SAN FRANCISCO · NEW YORK · ZURICH · NOT AN OFFER TO SELL SECURITIES OR LP INTERESTS.
FUND IV DEPLOYING // 48-HR GP REVIEW SLA